Product Description: Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
Applications: Metabolism-protein/nucleotide metabolism
Formula: N/A
References: [1]Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. /[2]Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.
CAS Number: 1407495-02-6
Molecular Weight: N/A
Compound Purity: 99.9
Research Area: Metabolic Disease; Cardiovascular Disease
Solubility: 10 mM in DMSO
Target: PCSK9
English
Deutsch
